Orphan drug development is progressing too slowly, Br J Clin Pharmacol, vol.61, issue.3, pp.355-60, 2006. ,
Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases, Orphanet J Rare Dis, vol.7, p.50, 2012. ,
Report Series -List of rare diseases -listed in alphabetical number, 2012. ,
Fact Sheet, 2007. ,
The rare disease challenge and how to promote a productive rare disease community: Case study of Birt-Hogg-Dube Symposia, Orphanet J Rare Dis, vol.7, p.63, 2012. ,
Contribution to the treatment of rare diseases: orphan drugs, J Eur Medical Writers Assoc Write Stuff, vol.18, issue.1, pp.21-24, 2009. ,
, EMA. Orphan Medicines Figures, 2000.
, Update, 2015.
, Current Results of Research, 2016.
, Guideline on clinical trials in small populations, CHMP, 2007.
, Concept paper on extrapolation of efficacy and safety in medicine development, EMA, 2012.
Diseases: Common Issues in Drug Development Guidance for Industry, 2015. ,
Benefits of pharmacometric model-based design and dnalysis of clinical trials, Acta Universitatis Upsaliensis, vol.133, 2010. ,
Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and rranslational research settings, J Clin Pharmacol, vol.48, p.632, 2008. ,
The Evaluation of Surrogate Endpoints, 2005. ,
The PCORI perspective on patient-centered outcomes research, J Am Med Assoc, vol.312, issue.15, pp.1513-1517, 2014. ,
Choosing important health outcomes for comparative effectiveness research: a systematic review, PLoS One, vol.9, p.6, 2014. ,
Goal attainment scaling: A general method for evaluating comprehensive community mental health programs, Community Ment Health J, vol.4, issue.6, pp.443-53, 1968. ,
The analysis of multiple endpoints in clinical trials, Biometrics, vol.43, issue.3, pp.487-98, 1987. ,
A uniform improvement of Bonferroni-type tests by sequential tests, J Am Stat Assoc, vol.103, issue.481, pp.299-308, 2008. ,
A graphical approach to sequentially rejective multiple test procedures, Stat Med, vol.28, issue.4, pp.586-604, 2009. ,
, European Organisation for Rare Diseases, 2016.
The impact of selection bias on test decisions in randomized clinical trials, Stat Med, vol.30, issue.21, pp.2573-81, 2011. ,
Adaptive designs for confirmatory clinical trials, Stat Med, vol.28, issue.8, pp.1181-217, 2009. ,
Clincal trials and rare diseases, Adv Exp Med Biol, vol.686, pp.173-90, 2010. ,
Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials, 2016. ,
A journey of hope: lessons learned from studies on rare diseases and orphan drugs, J Intern Med, vol.260, issue.1, pp.1-10, 2006. ,
Adaptive trials in clinical research: scientific and ethical issues to consider, JAMA, vol.307, issue.22, pp.2379-80, 2012. ,
What makes clinical research ethical?, JAMA, vol.283, issue.20, pp.2701-2712, 2000. ,
A framework for applying unfamiliar trial designs in studies of rare diseases, J Clin Epidemiol, vol.64, issue.10, pp.1085-94, 2011. ,
Experimental designs for small randomized clinical trials: an algorithm for choice, Orphanet J Rare Dis, vol.8, p.48, 2013. ,